Abstract 4297
Background
Anxiety and distress may be experienced by cancer patients diagnosed with melanoma throughout their diagnosis and treatment. Beaumont Hospital, Dublin is a designated cancer centre and a proposal to develop an onsite melanoma patient support group (MPSG) in collaboration with the Skin Oncology CNSp, and the Cancer Nurse, Daffodil Centre, Beaumont Hospital was agreed. Aims/Objectives: To assess the interest in attending a professionally facilitated MPSG. To ascertain what type of group would benefit most. To ascertain the themes required to meet the needs of the group. To offer a supportive, safe environment for meeting and sharing experiences. To create an awareness of the support required by patients diagnosed with melanoma.
Methods
Initial planning meeting between the Skin Oncology CNS and the Cancer Nurse, resulted in an agreement to develop a MPSG. A target population was identified and the practicalities and commitment involved in co-facilitating a support group were identified. Group governance was developed. An expression of interest letter and a questionnaire was sent to the target population, specific themes were incorporated to assist development of the support group and manage its format and content.
Results
Patient responses identified a format for the support group incorporating educational and emotional support. Group rules were established and adhered to, with regular evaluation and discussion taking place allowing change to be incorporated as required. Six meetings took place in 2018/2019.
Conclusions
Future plans include: Maintain stability of the group. Continue meeting every two months. Attract new members. Review of group by questionnaire in relation to specific patient interests.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract